Skip to main content

Avoid the Loss of Patient Data by Efficiently Finding Patients Lost to Follow-Up, New Webinar Hosted by Xtalks



Toronto, ON - March 22, 2018 - (Newswire.com)

In a live session on Thursday, April 5, 2018 at 11am EDT (4pm BST/UK, industry expert Bernard Hall, Project Manager at Bioclinica LTFU will discuss the latest techniques for how to avoid missing data due to lost patients during a clinical trial.

Missing patients, and therefore their data, pose a threat to clinical trials. This missing patient data increases the risk of additional queries from regulatory agencies regarding the potential effect on the endpoint data and therefore the significance of the safety and efficacy findings.

Study sites often lack the resources and time to find patients who are lost to follow-up (LTFU). Although there are patient tracking services available, they vary in their effectiveness in both finding, and then retaining, patients. Consideration of how to mitigate missing data from missing patients in the initial planning phase of a clinical trial can help identify how to avoid missing patients in the first place and how best to find patients who do drop out.

Join our presenter for an insightful discussion – and answers to your questions – on this clinically and commercially relevant topic. To learn more or to join this free webinar visit: Avoid the Loss of Patient Data by Efficiently Finding Patients Lost to Follow-Up

ABOUT BIOCLINICA

Bioclinica is a global life sciences solution provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica’s hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval.  The company’s cloud-based offerings include medical imaging; cardiac safety; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site payments and forecasting; pharmacovigilance; trial management; and risk-based monitoring solutions. A true multifaceted partner to trial sponsors and Contract Research Organizations (CROs), Bioclinica offers an integrated App xChange partner ecosystem, a global network of research sites, patient recruitment services, and post-approval research expertise to provide committed, detail-focused service through all stages of drug development.  The company’s thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Nima Rajan

Tel: +1 (416) 977-6555 ext 352​


Related Links
Webinar Details
More about Bioclinica

Related Images




Press Release Service by Newswire.com

Original Source: Avoid the Loss of Patient Data by Efficiently Finding Patients Lost to Follow-Up, New Webinar Hosted by Xtalks
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.